

I. Amendments to the Claims:

This listing of claims shall replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-61 (canceled)

Claim 62 (Previously Presented) A composition comprising an inert core, a first layer and a second layer, the first layer being between the core and the second layer, the first layer consisting essentially of an opioid antagonist and the second layer comprising a hydrophobic material.

Claim 63 (Previously Presented) A composition comprising an inert core, a first layer and a second layer, the first layer being between the core and the second layer, the first layer comprising naltrexone, nalmeferene, or pharmaceutically acceptable salts thereof and the second layer comprising a hydrophobic material.

Claim 64 (Previously Presented) The composition of claims 62 or 63, wherein the composition comprises from about 12% to about 15% hydrophobic material by weight of the composition.

Claim 65. (Previously Presented) An oral dosage form comprising an opioid agonist and the composition of claim 62.

Claim 66. (Previously Presented) The oral dosage form of claim 65, wherein the opioid agonist is alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphine, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacymorphan, lofentanil, meperidine, meptazinol,

metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, novlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, prophetazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, a pharmaceutically acceptable salt or mixtures thereof.

Claim 67. (Previously Presented) The oral dosage form of claim 66, wherein the opioid agonist is oxycodone or a pharmaceutically acceptable salt thereof.

Claim 68. (Withdrawn) The oral dosage form of claim 76, wherein the opioid agonist is hydrocodone or a pharmaceutically acceptable salt thereof.

Claim 69. (Previously Presented) An oral dosage form comprising an opioid agonist and the composition of claim 62 comprising from about 14% to about 22% hydrophobic material by weight of the oral dosage form.

Claim 70. (Previously Presented) The oral dosage form of claim 69, wherein the opioid agonist is alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphine, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacymorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, novlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, prophetazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, a pharmaceutically acceptable salt or mixtures thereof.

Claim 71. (Previously Presented) The oral dosage form of claim 65 wherein the opioid antagonist is naltrexone, naloxone, nalmefene, cyclazacine, levallorphan, a pharmaceutically acceptable salt or a mixture thereof.

Claim 72. (Previously Presented) The oral dosage form of claim 69, wherein the opioid antagonist is naltrexone, naloxone, nalmefene, cyclazacine, levallorphan, a pharmaceutically acceptable salt or a mixture thereof.

Claim 73. (Previously Presented) A method for treating pain, comprising administering to a human patient in need thereof an effective amount of an oral dosage form comprising an opioid agonist and the composition of claim 62.

Claim 74. (Previously Presented) A method for treating pain, comprising administering to a human patient in need thereof an effective amount of an oral dosage form comprising an opioid agonist and the composition of claim 62 comprising from about 14% to about 22% hydrophobic material by weight of the oral dosage form.